Related Experiment Videos
Prostate carcinoma: immunostaging and adjuvant immunotherapy with BCG
National Cancer Institute Monograph
|December 1, 1978
Summary
Immunostaging may help assess prostate cancer progression. Adjuvant Bacillus Calmette-Guérin (BCG) immunotherapy showed improved survival rates and minimal side effects in prostate cancer patients.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Prostate adenocarcinoma diagnosis requires accurate staging.
- Immunological assessment can provide prognostic information.
- Adjuvant immunotherapy is being explored for prostate cancer treatment.
Purpose of the Study:
- To evaluate immunostaging as a method for assessing prostate cancer patients.
- To determine the efficacy and safety of Bacillus Calmette-Guérin (BCG) as adjuvant immunotherapy for prostate cancer.
Main Methods:
- Thirty-three patients with prostate adenocarcinoma underwent immunostaging using humoral and cellular immune parameters.
- Nineteen patients received adjuvant BCG immunotherapy alongside conventional therapy; 14 served as controls.
Main Results:
- A positive correlation was observed between immunostage and clinical stage in prostate cancer patients.
- Patients receiving BCG immunotherapy demonstrated a longer mean survival time compared to controls.
- BCG immunotherapy resulted in minimal morbidity and no mortality.
Conclusions:
- Immunostaging shows promise in correlating with prostate cancer clinical stage.
- Adjuvant BCG immunotherapy appears to be a safe and effective treatment for improving survival in prostate cancer patients.